Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
09/14/2020 09/15/2020 09/16/2020 09/17/2020 09/18/2020 Date
1632 1616 1611 1619 1626.5 Last
3507900 3680100 3592000 2942100 5881900 Volume
+0.71% -0.98% -0.31% +0.50% +0.46% Change
Financials
Sales 2021 1 274 B 12 183 M 12 183 M
Net income 2021 205 B 1 956 M 1 956 M
Net cash position 2021 450 B 4 301 M 4 301 M
P/E ratio 2021 14,7x
Yield 2021 2,59%
Sales 2022 1 347 B 12 876 M 12 876 M
Net income 2022 231 B 2 210 M 2 210 M
Net cash position 2022 578 B 5 524 M 5 524 M
P/E ratio 2022 12,9x
Yield 2022 2,85%
Capitalization 3 021 B 28 937 M 28 889 M
EV / Sales 2021 2,02x
EV / Sales 2022 1,81x
Nbr of Employees 15 883
Free-Float 99,2%
More Financials
Company
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%). 
More about the company
Notations Surperformance© of Astellas Pharma Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ASTELLAS PHARMA INC.
09/02Japan shares rise on hopes for U.S. economy, new prime minister eyed
RE
09/01Japan stocks rise on U.S. data, easing concerns about new prime minister
RE
08/24ASTELLAS PHARMA INC. : - Science-Based Fitness Service, Fit-eNce
AQ
08/11Bayer takes on Astellas in purchase of experimental menopause relief
RE
08/10ASTELLAS PHARMA : Open Innovation Challenge Astellas Rx+ Healthcare Innovation C..
AQ
07/30ASTELLAS PHARMA INC. : quaterly earnings release
07/23ASTELLAS PHARMA : is Awarded Grant from the U.S. National Institutes of Health t..
AQ
07/20ASTELLAS PHARMA : Named to FTSE4Good Index Series for Ninth Consecutive Year
AQ
06/17ASTELLAS PHARMA : Efforts against the Spread of the Coronavirus Disease
AQ
06/10Japanese shares end almost flat just below three-month high as rally loses st..
RE
06/09ASTELLAS PHARMA : Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phas..
AQ
06/05ASTELLAS PHARMA : City of Yokohama, and Yokohama City University Developed Scien..
AQ
06/03ASTELLAS PHARMA : Federal Circuit Reverses PTAB Finding Tarceva® Method Of Treat..
AQ
05/28ASTELLAS PHARMA INC. : - FDA Approves VESIcare LS Oral Suspension for Pediatric ..
AQ
05/21ASTELLAS PHARMA INC. : - Notice Regarding Continuation of the Performance-linked..
AQ
More news
News in other languages on ASTELLAS PHARMA INC.
07/30ASTELLAS PHARMA INC. : Veröffentlichung des Quartalsergebnisses
07/30ASTELLAS PHARMA INC. : publication des résultats trimestriels
05/28Basileas klinische Studien liegen trotz Corona mehr oder weniger im Zeitplan
05/11ASTELLAS PHARMA INC. : Veröffentlichung des Jahresergebnisses
05/11ASTELLAS PHARMA INC. : publication des résultats annuels
More news
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 275,00 JPY
Last Close Price 1 626,50 JPY
Spread / Highest target 66,0%
Spread / Average Target 39,9%
Spread / Lowest Target 4,52%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-13.02%28 937
JOHNSON & JOHNSON2.27%392 765
ROCHE HOLDING AG9.27%322 209
MERCK & CO., INC.-5.65%217 034
PFIZER, INC.-6.02%203 549
NOVARTIS AG-9.76%200 978